Source: Annual Congress 2001 - Inflammatory and genetic mechanisms in pulmonary fibrosis
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
T. M. Zielonka, U. Demkow, M. Filewska, B. Bialas, E. Radzikowska, A. Soszka, P. Remiszewski, J. Szopinski, E. Wiatr, E. Skopinska-Rozewska (Warsaw, Poland). TNFα and INFγ inducing capacity of sera from interstitial lung diseases (ILD) patients in relation to its angiogenic activity. Eur Respir J 2001; 16: Suppl. 31, 2779

Member's Comments

No comment yet.

Related content which might interest you: Relationships between angiogenic activity of sera from interstitial lung disease (ILD) patients and lung function tests Source: Eur Respir J 2002; 20: Suppl. 38, 106s Year: 2002 Reduced anti-oxidant and increased inflammatory status in interstitial lung diseases (ILD) Source: Eur Respir J 2007; 30: Suppl. 51, 110s Year: 2007 Angiogenic activity of sera from patients with various types of pulmonary fibrosis in relation to pulmonary functions Source: Annual Congress 2009 - Pathological remodelling in chronic lung disease: from epithelial-mesenchymal transition to cellular activation Year: 2009 The markers of inflammatory process activity and fybrogenesis activity in patients with idiopathic pulmonary fibrosis Source: Annual Congress 2012 - Diffuse parenchymal lung disease I Year: 2012 The influence of sera from interstitial lung diseases (ILD) patients on human mononuclear cells (MNC) production of vascular endothelial growth factor (VEGF) Source: Eur Respir J 2004; 24: Suppl. 48, 553s Year: 2004 Low apoptosis rate as a reason of local immune cell accumulation in interstitial lung diseases (ILD). The role of cytokine network Source: Eur Respir J 2006; 28: Suppl. 50, 826s Year: 2006 The Gender-Age-Physiology (GAP) Index enhanced with KL-6 serum level for predicting disease progression in interstitial lung diseases (ILD). Source: Virtual Congress 2020 – Predictive markers of progression in connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis Year: 2020 Modified GAP index by including serum KL-6 to assess risk of disease progression in patients with interstitial lung diseases (ILD): preliminary results from the VAMOS study. Source: Virtual Congress 2021 – New approaches to diagnostic and prognostic evaluation of interstitial lung diseases of known causes Year: 2021 Alveolar lymphocytes (AL) apoptosis in interstitial lung diseases (ILD). Increased AL apoptosis rate in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2009 - Pathogenesis of pulmonary fibrosis Year: 2009 B cell activating factor belonging to the TNF family might be a useful biomarker in interstitial lung diseases associated with connective tissue diseases Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013 The role of secondary pulmonary hypertension (SPH) in the limited exercise tolerance of patients with interstitial lung disease (ILD) Source: Eur Respir J 2005; 26: Suppl. 49, 560s Year: 2005 Broncholaveolar lavage (BAL) lymphocytes from patients with interstitial lung diseases (ILD) produce hepatocyte growth factor (HGF) Source: Annual Congress 2009 - Bronchoalveolar lavage and phenotyping in diffuse parenchymal lung disease Year: 2009 Expression of hyaluronidase by interstitial myofibroblasts and epithelial cells is associated with fibrosis extension, clinical forms and pulmonary function stage in patients with systemic sclerosis Source: Annual Congress 2010 - Pathogenesis of diffuse parenchymal lung disease Year: 2010 Effects of pulmonary rehabilitation in patients with interstitial lung disease (ILD) Source: Annual Congress 2009 - New treatment and outcome measures for pulmonary rehabilitation Year: 2009 UIP-like or NSIP pattern in interstitial lung disease patients (ILD), following by ‘connective tissue disease ‘(CTD) Source: Annual Congress 2012 - Diffuse parenchymal lung disease III Year: 2012 Clinical characteristics of 30 patients with interstitial pneumonia associated with anti-aminoacyl-tRNA-synthetase antibodies Source: International Congress 2016 – Connective tissue disorders Year: 2016 Telomerase expression in idiopathic pulmonary fibrosis (IPF) and non small cell lung cancer (NSCLC) Source: Annual Congress 2012 - Diffuse parenchymal lung disease: clinical profiles and collagen vascular disease Year: 2012 Lysozyme level and activity are decreased in the lungs of patients with idiopathic pulmonary fibrosis (IPF) and potentially contribute to increased susceptibility to pulmonary infection Source: Annual Congress 2006 - Usefulness of broncoalveolar lavage (BAL) in interstitial lung diseases Year: 2006 Antigen presenting cells of lower airways in interstitial lung diseases (ILD). Do alveolar lymphocytes possess the ability to present antigens? Source: Annual Congress 2010 - Clinical issues in diffuse parenchymal lung disease Year: 2010